Melanoma vaccine cuts recurrence and death risk by 42 percent in trial

A world-first personalized messenger RNA vaccine has demonstrated a dramatic reduction in the risk of melanoma returning or resulting in death when administered alongside established immunotherapy, according to global clinical trial results presented at the European Society for Medical Oncology Congress 2026. The late-stage trial evaluated the experimental treatment in patients with high-risk skin cancer, marking what medical professionals have termed a foundational shift in precision oncology.

Developed jointly by Moderna and Merck, the bespoke therapy—known as intismeran autogene—applies genetic sequencing to individual tumors according to Stock Titan. Following surgical removal of a patient's melanoma, laboratory analysts identify distinct mutational fingerprints, known as neoantigens, that differentiate cancerous cells from healthy tissue. A synthetic messenger RNA strand is then custom-built to encode up to 34 of these unique markers, acting as a biological wanted poster reported Yahoo News.

Media additions

When injected into the patient, the mRNA instructs local cells to manufacture copies of these mutated proteins, training the immune system to actively hunt down and destroy any remaining microscopic cancer cells. This treatment is administered alongside pembrolizumab, marketed commercially as Keytruda. While the vaccine provides targeted coordinates for the immune system, the checkpoint inhibitor blocks cellular mechanisms that tumors use to evade detection noted ScienceAlert.

The global Phase 3 study, designated as INTerpath-001, enrolled more than 1,100 participants across 157 clinical sites worldwide. Patients with completely resected stage IIB-IV cutaneous melanoma were randomized to receive either the combination therapy or pembrolizumab alone reported Stock Titan. After a median follow-up of 24.6 months, the primary analysis revealed that the vaccine combination significantly reduced the risk of recurrence or death by 42 percent compared to the control arm according to Stock Titan.

Independent oncology specialists have praised the findings as a watershed moment for clinical research.

"These findings are a foundational shift in our approach to cancer: harnessing the immune system in a more personalized way to reduce the risk of melanoma recurrence or death"

Georgina Long, global principal investigator and medical oncologist from the Melanoma Institute Australia, via Yahoo News

Long presented the data at the European gathering, with additional publication expected in the New England Journal of Medicine.

Financial markets reacted sharply to the disclosures. Shares of Moderna experienced significant volatility, tumbling in initial trading sessions following the leak of preliminary data ahead of the formal presentation, while analysts debated whether the figures met lofty investor expectations reported BioPharma Dive. Despite short-term market adjustments, executives emphasized that regulatory discussions are actively underway noted Stock Titan.

Safety evaluations showed that treatment-related adverse events occurred in the majority of patients receiving the vaccine combination compared to the control group according to Stock Titan. Grade 3 to 5 adverse events remained comparable across both cohorts, though vaccinated patients experienced higher frequencies of pyrexia, injection-site pain, and fatigue reported Stock Titan. Approximately 7 percent of participants receiving the custom vaccine discontinued treatment due to adverse reactions stated BioPharma Dive.

Broader implications for the technology remain under active investigation. While the melanoma trial succeeded, several randomized trials testing similar mRNA vaccines in colorectal cancer and head and neck cancer have recently failed to reduce recurrence noted Yahoo News. Nevertheless, Merck and Moderna are continuing a robust clinical development program encompassing multiple tumor types, including ongoing Phase 3 trials in non-small cell lung cancer reported Stock Titan.

Further updates on overall survival endpoints and upcoming regulatory filings are expected as the ongoing clinical trials proceed according to Stock Titan.